Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

A common functional variant in paraoxonase 1 (PON1), Q192R, was recently reported to be a major determinant of clopidogrel response. This variant was genotyped in 566 participants of the Amish Pharmacogenomics of Anti-Platelet Intervention (PAPI) study and in 227 percutaneous coronary intervention (PCI) patients. Serum paraoxonase activity was measured in a subset of 79 PAPI participants. PON1 Q192R was not associated with pre- or post-clopidogrel platelet aggregation in the PAPI study (P = 0.16 and P = 0.21, respectively) or the PCI cohort (P = 0.47 and P = 0.91, respectively). The Q192 allele was not associated with cardiovascular events (hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.20-1.06; P = 0.07). No correlation was observed between paraoxonase activity and post-clopidogrel platelet aggregation (r(2) < 0.01, P = 0.78). None of 49 additional PON1 variants evaluated was associated with post-clopidogrel platelet aggregation. These findings do not support a role for PON1 as a determinant of clopidogrel response.

Full Text

Duke Authors

Cited Authors

  • Lewis, JP; Fisch, AS; Ryan, K; O'Connell, JR; Gibson, Q; Mitchell, BD; Shen, H; Tanner, K; Horenstein, RB; Pakzy, R; Tantry, US; Bliden, KP; Gurbel, PA; Shuldiner, AR

Published Date

  • October 2011

Published In

Volume / Issue

  • 90 / 4

Start / End Page

  • 568 - 574

PubMed ID

  • 21881565

Pubmed Central ID

  • PMC3250350

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1038/clpt.2011.194


  • eng

Conference Location

  • United States